

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

**INSIDE INFORMATION ANNOUNCEMENT
GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE
H SHARE FULL CIRCULATION PLAN OF THE COMPANY**

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

References are made to the announcements dated May 21, 2025 and January 30, 2026 of the Company (the “**Announcements**”) in relation to, among others, the proposed participation in the H Share Full Circulation by the Company and the issuance of filing notice by the CSRC for the H Share Full Circulation plan of the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE

The Company is pleased to announce that it received the approval granted by the Stock Exchange on February 5, 2026 for the listing of and permission to deal in 141,953,489 H shares (the “**Converted H Shares**”) (the “**Listing Approval**”).

SHAREHOLDING STRUCTURE

The Conversion and Listing will involve a total of 28 participating shareholders (the “**Participating Shareholders**”) holding an aggregate of 141,953,489 unlisted shares of the Company. Upon completion of the Conversion and Listing, the shareholdings of the Participating Shareholders in the Company are set out as follows:

No.	Name of Participating Shareholders	Class of shares	Number of Converted H Shares (share)	Approximate percentage of the total issued shares of the Company upon completion of the Conversion and Listing
1	LIU Yong	Domestic shares	193,943	0.0310%
2	Taizhou Yuangong Technology Partnership (Limited Partnership)	Domestic shares	62,147,715	9.9265%
3	Taizhou Ruibaitai Pharmaceutical Technology Partnership (Limited Partnership)	Domestic shares	8,076,923	1.2901%
4	Taizhou Baibei Biotechnology Partnership (Limited Partnership)	Domestic shares	1,143,750	0.1827%
5	Taizhou Guquan Biotechnology Partnership (Limited Partnership)	Domestic shares	1,143,750	0.1827%
6	Beijing Junlian Shengyuan Equity Investment Enterprise (Limited Partnership)	Domestic shares	7,084,855	1.1316%
7	Zhuhai Junlian Yongshuo Equity Investment Enterprise (Limited Partnership)	Domestic shares	3,380,400	0.5399%
8	Shenzhen Fuhai Juanyong II Venture Capital Enterprise (Limited Partnership)	Domestic shares	1,817,340	0.2903%
9	Shenzhen Fuhai Juanyong III Venture Capital Enterprise (Limited Partnership)	Domestic shares	346,153	0.0553%
10	Shenzhen Qianhai Kekong Fuhai Youxuan Venture Capital Investment Partnership (Limited Partnership)	Domestic shares	330,425	0.0528%
11	Shenzhen Fuhai Youxuan II High Technology Venture Capital Investment Partnership (Limited Partnership)	Domestic shares	230,770	0.0369%
12	Shenzhen Nanshan OFC Small and Medium Venture Capital Investment Fund Partnership (Limited Partnership)	Domestic shares	165,213	0.0264%
13	Shenzhen Yingkejin Investment Management Partnership (Limited Partnership)	Domestic shares	4,525,393	0.7228%
14	Liuyang Woyang Health Industry Investment Partnership (Limited Partnership)	Domestic shares	2,081,680	0.3325%
15	Changsha Woyang Phase II Health Industry Investment Partnership (Limited Partnership)	Domestic shares	2,031,287	0.3244%
16	Shenzhen Luewei Investment Management Partnership (Limited Partnership)	Domestic shares	429,553	0.0686%

No.	Name of Participating Shareholders	Class of shares	Number of Converted H Shares (share)	Approximate percentage of the total issued shares of the Company upon completion of the Conversion and Listing
17	Shenzhen Hanchen Venture Capital Fund Partnership (Limited Partnership)	Domestic shares	4,481,250	0.7158%
18	Ningbo Meishan Bonded Port Areas Haojin Zhitong Venture Capital Investment Partnership (Limited Partnership)	Domestic shares	2,645,927	0.4226%
19	Ganzhou Haojin Zhiyuan Equity Investment Center (Limited Partnership)	Domestic shares	2,164,947	0.3458%
20	Nanjing Tsingsong Medical Health Industry Investment Partnership (Limited Partnership)	Domestic shares	1,758,325	0.2808%
21	Shenzhen Tsingsong Chengtong Investment Partnership (Limited Partnership)	Domestic shares	1,383,325	0.2210%
22	Wuhan Chengyelian Equity Investment Enterprise (Limited Partnership)	Domestic shares	2,551,150	0.4075%
23	Guangdong Yifang Tengda Equity Investment Partnership (Limited Partnership)	Domestic shares	1,250,000	0.1997%
24	Yifang Huida Venture Capital (Guangdong) Investment Partnership (Limited Partnership)	Domestic shares	1,250,000	0.1997%
25	Jiangsu Taizhou Guangkong Industry Investment Partnership (Limited Partnership)	Domestic shares	991,275	0.1583%
26	Springleaf Investments Pte. Ltd.	Unlisted foreign shares	12,000,000	1.9167%
27	Shanghai Jiyue Enterprise Management Partnership (Limited Partnership)	Domestic shares	8,318,800	1.3287%
28	Shanghai Jixuan Enterprise Management Consulting Partnership (Limited Partnership)	Domestic shares	8,029,340	1.2825%
Total			141,953,489	22.6735%

The shareholding structure of the Company as at the date of this announcement and upon the completion of the Conversion and Listing is set out below:

Class of shares	As at the date of this announcement		Upon completion of the Conversion and Listing	
	Number of shares	Approximate percentage of the total issued shares of the Company	Number of shares	Approximate percentage of the total issued shares of the Company
Domestic shares	297,937,013	47.59%	167,983,524	26.83%
Unlisted foreign shares	12,000,000	1.92%	0	0.00%
H shares	316,138,689	50.50%	458,092,178	73.17%
Total	626,075,702	100.00%	626,075,702	100.00%

Note: Percentages have been rounded to the nearest two decimal places. Any discrepancy between the totals and the sum of the individual figures set out in this announcement is due to rounding.

The Company will complete the relevant conversion and trading procedures in relation to the Converted H Shares. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, February 6, 2026

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the Chairman of the Board and a non-executive director, Dr. LIU Yong, Mr. WEI Qifang and Ms. WANG Jing as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiabin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.